Cara Therapeutics prices IPO at $11, the low end of the range

By
A A A

Cara Therapeutics, a Phase 3-stage biotech developing a novel opioid pain medication, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Cara Therapeutics plans to list on the NASDAQ under the symbol CARA. Cara Therapeutics initially filed confidentially on 10/4/2013. Stifel and Piper Jaffray acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CARA

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com